Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Stock analysts at assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZSGet Rating) (TSE:AEZ) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Trading Up 7.5 %

Shares of NASDAQ AEZS opened at $5.57 on Wednesday. The stock has a market cap of $27.05 million, a P/E ratio of -2.63 and a beta of 1.39. Aeterna Zentaris has a 12-month low of $4.11 and a 12-month high of $24.38. The business’s fifty day simple moving average is $4.93 and its 200-day simple moving average is $6.81.

About Aeterna Zentaris

(Get Rating)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications.

Further Reading

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.